Cargando…
β-amyloid and tau drive early Alzheimer’s disease decline while glucose hypometabolism drives late decline
Clinical trials focusing on therapeutic candidates that modify β-amyloid (Aβ) have repeatedly failed to treat Alzheimer’s disease (AD), suggesting that Aβ may not be the optimal target for treating AD. The evaluation of Aβ, tau, and neurodegenerative (A/T/N) biomarkers has been proposed for classify...
Autores principales: | Hammond, Tyler C., Xing, Xin, Wang, Chris, Ma, David, Nho, Kwangsik, Crane, Paul K., Elahi, Fanny, Ziegler, David A., Liang, Gongbo, Cheng, Qiang, Yanckello, Lucille M., Jacobs, Nathan, Lin, Ai-Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338410/ https://www.ncbi.nlm.nih.gov/pubmed/32632135 http://dx.doi.org/10.1038/s42003-020-1079-x |
Ejemplares similares
-
Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
por: Pascoal, T A, et al.
Publicado: (2017) -
Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients
por: Yang, Zhengshi, et al.
Publicado: (2023) -
Precision of declination drive
por: Richter, W
Publicado: (1971) -
BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease
por: Kim, Jun Pyo, et al.
Publicado: (2021) -
Cognitive decline and brainstem hypometabolism in long COVID: A case series
por: Hugon, Jacques, et al.
Publicado: (2022)